Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE,Md. and SUZHOU,China,Jan. 5,2023 -- Innovent Biologics,Inc. ("Innovent","the Company") (HKEX: 01801),a world-class biopharmaceutical company that develops,manufactures and commercializes high quality medicines for the treatment of oncology,autoimmune,metabolic,ophthalmology and other major diseases,today announced that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference held on January 9-12,2023 in San Francisco and Dr. De-Chao Michael Yu,Founder,Chairman and CEO of Innovent will present on Wednesday,January 11,2023 at 10:00am Pacific Standard Time.
A live webcast (audio) of the presentation can be accessed at:
https://jpmorgan.metameetings.net/events/healthcare23/sessions/44016-innovent-biologics-inc/webcast?gpu_only=true&kiosk=true
A replay of the webcast (active for up to 30 days ) and presentation slides will be available on the Innovent website - Investors & Media section following the live presentation:
https://www.innoventbio.com/InvestorsAndMedia/WebcastsAndPresentations
About Innovent
Inspired by the spirit of "Start with Integrity,Succeed through Action," Innovent's mission is to develop,manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011,Innovent is committed to developing,manufacturing and commercializing high-quality innovative medicines for the treatment of cancer,autoimmune disease,metabolic disorder and other major diseases. On October 31,2018,Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception,Innovent has developed a fully integrated multi-functional platform which includes R&D,CMC (Chemistry,Manufacturing,and Controls),clinical development and commercialization capabilities. Leveraging the platform,the company has built a robust pipeline of 36 valuable assets in the fields of cancer,metabolic disorder,autoimmune disease and other major therapeutic areas,with 8 approved products on the market. These include: TYVYT® (sintilimab injection),BYVASDA® (bevacizumab biosimilar injection),SULINNO® (adalimumab biosimilar injection),HALPRYZA® (rituximab biosimilar injection),Pemazyre® (pemigatinib oral inhibitor),olverembatinib (BCR-ABL TKI),Cyramza® (ramucirumab)and Retsevmo® (selpercatinib). An additional 2 assets are under NMPA NDA review,6 assets are in Phase 3 or pivotal clinical trials,and 20 more molecules are in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization,including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company,Sanofi,Adimab,Incyte,MD Anderson Cancer Center and other international partners. Innovent strives to work with many collaborators to help advance China's biopharmaceutical industry,improve drug availability and enhance the quality of the patients' lives. For more information,please visit: www.innoventbio.com. and www.linkedin.com/company/innovent-biologics/.
Note:
TYVYT® (sintilimab injection) is not an approved product in the United States.
BYVASDA® (bevacizumab biosimilar injection),SULINNO®,and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States.
TYVYT® (sintilimab injection,Innovent)
BYVASDA® (bevacizumab biosimilar injection,Innovent)
HALPRYZA® (rituximab biosimilar injection,Innovent)
SULINNO® (adalimumab biosimilar injection,Innovent)
Pemazyre® (pemigatinib oral inhibitor,Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China,Hong Kong,Macau and Taiwan.
CYRAMZA® (ramucirumab,Eli Lilly). Cyramza® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.
Retsevmo® (selpercatinib,Eli Lilly). Retsevmo® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are,by their nature,subject to significant risks and uncertainties. The words "anticipate","believe","estimate","expect","intend" and similar expressions,as they relate to Innovent,are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs,assumptions,expectations,estimates,projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks,uncertainties and other factors,some of which are beyond Innovent's control and are difficult to predict. Consequently,actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business,Innovent's competitive environment and political,economic,legal and social conditions.
Innovent,the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
